Global Contrast Media Market

Contrast Media Market Size, Share, Growth Analysis, By Type(Iodinated Contrast Media, Gadolinium-based Contrast Media, Microbubble Contrast Media, Barium-based Contrast Media), By Form(Liquid Contrast Media, Powder Contrast Media, Other Forms), By Modality(X-RAY, CT, MRI, Ultrasound), By Route of Administration(Intravascular Route [Intravenous (IV) route, Intra-arterial (IA) route], Oral Route, Rectal Route), By Indication(Cardiovascular Disease, Cancer, Gastrointestinal Disorders, Musculoskeletal Disorders), By Application(Radiology, Interventional Radiology, Interventional Cardiology), By End User(Hospitals, Clinics, And Ambulatory Surgery Centers, Diagnostic Imaging Centers), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35B2070 | Region: Global | Published Date: September, 2024
Pages: 260 | Tables: 91 | Figures: 75

Contrast Media Market Competitive Landscape

To increase their market share in the market, major firms are implementing tactics including collaborations, acquisitions, and mergers. They are also introducing new goods.

Major players are engaging in mergers and acquisitions to broaden their consumer bases and market shares globally. Acquisitions help businesses grow their footprint by giving them a broader geographic reach and a better portfolio. In this sector, disease indication extension is common since it helps businesses win over the trust of specific population segments. Companies can target specialized patient demographics and increase the acceptance of their goods through approvals for particular indications.

Contrast Media Market Top Player's Company Profiles

  • GE Healthcare (US) 
  • Bracco Imaging S.p.A. (Italy) 
  • Bayer AG (Germany) 
  • Guerbet (France) 
  • Lantheus Medical Imaging (US) 
  • Unijules Life Sciences Ltd. (India) 
  • J.B. Chemicals & Pharmaceuticals Limited (India) 
  • Taejoon Pharm Co., Ltd. (South Korea) 
  • Jodas Expoim (India) 
  • Imax Diagnostic Imaging Limited (Ireland) 
  • Yangtze River Pharmaceutical Group (China) 
  • Livealth Biopharma (India) 
  • Beijing Beilu Pharmaceutical Co., Ltd. (China) 
  • Unispire Biopharma Private Limited (India) 
  • Arco Lifesciences (I) Pvt. Ltd. (India) 
  • Stanex Drugs & Chemicals Pvt. Ltd. (India) 
  • Rege Imaging & Cine Films Private Limited (India) 
  • K Diam Exim (India) 
  • Onko Ilaç San. ve Tic. A.S. (Turkey) 
  • Fresenius Kabi (Germany) 
  • Biem Ilaç San. ve Tic. A.S. (Turkey) 
  • Advacare Pharma (US)

Contrast Media Market

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Contrast Media Market size was valued at USD 6.10 billion in 2022 and is poised to grow from USD 6.55 billion in 2023 to USD 11.60 billion by 2031, growing at a CAGR of 7.4% during the forecast period (2024-2031).

To increase their market share in the market, major firms are implementing tactics including collaborations, acquisitions, and mergers. They are also introducing new goods. 'GE Healthcare (US) ', 'Bracco Imaging S.p.A. (Italy) ', 'Bayer AG (Germany) ', 'Guerbet (France) ', 'Lantheus Medical Imaging (US) ', 'Unijules Life Sciences Ltd. (India) ', 'J.B. Chemicals & Pharmaceuticals Limited (India) ', 'Taejoon Pharm Co., Ltd. (South Korea) ', 'Jodas Expoim (India) ', 'Imax Diagnostic Imaging Limited (Ireland) ', 'Yangtze River Pharmaceutical Group (China) ', 'Livealth Biopharma (India) ', 'Beijing Beilu Pharmaceutical Co., Ltd. (China) ', 'Unispire Biopharma Private Limited (India) ', 'Arco Lifesciences (I) Pvt. Ltd. (India) ', 'Stanex Drugs & Chemicals Pvt. Ltd. (India) ', 'Rege Imaging & Cine Films Private Limited (India) ', 'K Diam Exim (India) ', 'Onko Ilaç San. ve Tic. A.S. (Turkey) ', 'Fresenius Kabi (Germany) ', 'Biem Ilaç San. ve Tic. A.S. (Turkey) ', 'Advacare Pharma (US)'

The demand for diagnostic imaging treatments and, consequently, contrast media has significantly increased as a result of the growing incidence of chronic illnesses throughout the world. In order to provide new goods to the market and get the contrast media authorized for new indications, contrast media makers have been doing substantial R&D as a consequence of the rising demand for imaging operations. For instance, the 20-vial pack design of the ultrasound contrast agent Lumason was approved by the US FDA in 2021 for use by Bracco.

A kind of intravenous radiocontrast (radiographic dye) called iodinated contrast medium makes vascular systems and organs more visible during radiographic operations. The iodinated contrast has aided in the identification of disorders like cancer by improving visibility. The 2, 4, and 6 tri-iodinated benzene rings were chemically modified to create the iodinated contrast media that are currently in use.

North America held the largest share of the global contrast media market in 2021. It was roughly 44.44%. This is expected to change as a result of numerous strategic initiatives done by important manufacturers to target certain patient subgroups in this area. GE Healthcare, Guerbet, Lantheus, and Bracco Diagnostics are some of the major market participants.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Contrast Media Market

Report ID: SQMIG35B2070

$5,300
BUY NOW GET FREE SAMPLE